Want to see OLMA full AI Analyst Report?
Olema Pharmaceuticals (OLMA) Stock Statistics & Valuation Metrics
Total Valuation
Olema Pharmaceuticals has a market cap or net worth of $641.36M. The enterprise value is $849.31M.
- Market Cap
- $641.36M
- Enterprise Value
- $849.31M
Share Statistics
Olema Pharmaceuticals has 87,497,604 shares outstanding. The number of shares has decreased by -2.65% in one year.
- Shares Outstanding
- 87,497,604
- Owned by Insiders
- 10.18%
- Owned by Institutions
- 43.54%
Financial Efficiency
Olema Pharmaceuticals’s return on equity (ROE) is -0.34 and return on invested capital (ROIC) is -37.02%.
- Return on Equity (ROE)
- -0.34
- Return on Assets (ROA)
- -0.30
- Return on Invested Capital (ROIC)
- -37.02%
- Return on Capital Employed (ROCE)
- -0.37
- Revenue Per Employee
- 0
- Profits Per Employee
- -1.08M
- Employee Count
- 150
- Asset Turnover
- 0.00
- Inventory Turnover
- 0.00
Valuation Ratios
The current PE Ratio of Olema Pharmaceuticals is -3.47. Olema Pharmaceuticals’s PEG ratio is 0.68.
- PE Ratio
- -3.47
- PS Ratio
- 0.00
- PB Ratio
- 1.79
- Price to FCF
- -3.91
- Price to Operating Cash Flow
- -4.67
- PEG Ratio
- 0.68
Income Statement
In the last 12 months, Olema Pharmaceuticals had revenue of 0 and earned -162.45M in profits. Earnings per share was -1.87.
- Revenue
- 0
- Gross Profit
- 0
- Operating Income
- -178.70M
- Pretax Income
- -162.45M
- Net Income
- -162.45M
- EBITDA
- -161.96M
- Earnings Per Share (EPS)
- -1.87
Cash Flow
In the last 12 months, operating cash flow was -164.74M and capital expenditures 0, giving a free cash flow of -164.74M billion.
- Operating Cash Flow
- -164.74M
- Free Cash Flow
- -164.74M
- Free Cash Flow per Share
- -1.58
Dividends & Yields
Olema Pharmaceuticals pays an annual dividend of ―, resulting in a dividend yield of ―
- Dividend Per Share
- ―
- Dividend Yield
- ―
- Payout Ratio
- N/A
- Free Cash Flow Yield
- -25.58%
- Earnings Yield
- -26.61%
Stock Price Statistics
- Beta
- 1.08
- 52-Week Price Change
- -10.50%
- 50-Day Moving Average
- 8.49
- 200-Day Moving Average
- 13.33
- Relative Strength Index (RSI)
- 47.34
- Average Volume (3m)
- 1.22M
Important Dates
Olema Pharmaceuticals upcoming earnings date is Nov 10, 2026, TBA (Not Confirmed).
- Last Earnings Date
- Nov 10, 2026
- Next Earnings Date
- Nov 10, 2026
- Ex-Dividend Date
- ―
Financial Position
Olema Pharmaceuticals as a current ratio of 9.95, with Debt / Equity ratio of 0.25%
- Current Ratio
- 9.95
- Quick Ratio
- 9.95
- Debt to Market Cap
- 0.00
- Net Debt to EBITDA
- 0.29
- Interest Coverage Ratio
- 0.00
Taxes
In the past 12 months, Olema Pharmaceuticals has paid 0 in taxes.
- Income Tax
- 0
- Effective Tax Rate
- 0.00
Enterprise Valuation
Olema Pharmaceuticals EV to EBITDA ratio is -2.92, with an EV/FCF ratio of -3.62.
- EV to Sales
- 0.00
- EV to EBITDA
- -2.92
- EV to Free Cash Flow
- -3.62
- EV to Operating Cash Flow
- -3.62
Balance Sheet
Olema Pharmaceuticals has $461.07M in cash and marketable securities with $660.00K in debt, giving a net cash position of $460.41M billion.
- Cash & Marketable Securities
- $461.07M
- Total Debt
- $660.00K
- Net Cash
- $460.41M
- Net Cash Per Share
- $5.26
- Tangible Book Value Per Share
- $4.12
Margins
Gross margin is 0.00%, with operating margin of 0.00%, and net profit margin of 0.00%.
- Gross Margin
- 0.00%
- Operating Margin
- 0.00%
- Pretax Margin
- 0.00%
- Net Profit Margin
- 0.00%
- EBITDA Margin
- 0.00%
- EBIT Margin
- 0.00%
Analyst Forecast
The average price target for Olema Pharmaceuticals is $33.43, which is 11.43% higher than the current price. The consensus rating is Strong Buy
- Price Target
- $33.43
- Price Target Upside
- 356.05% Upside
- Analyst Consensus
- Strong Buy
- Analyst Count
- 8
- Revenue Growth Forecast
- ―
- EPS Growth Forecast
- -10.16%
Scores
- Smart Score
- 4
- AI Score
- 49
